We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
SWOG 2114: A RANDOMIZED PHASE II TRIAL OF CONSOLIDATION THERAPY FOLLOWING CD19 CAR T‐CELL TREATMENT FOR RELAPSED/REFRACTORY LARGE B‐CELL OR GRADE IIIB FOLLICULAR LYMPHOMA.
- Authors
Hess, B.; Li, H.; Hossain, N.; Beylergil, V.; Sauter, C.; Hamadani, M.; Svoboda, J.; Major, A.; Kahl, B.; Leonard, J. P; Smith, S.; LeBlanc, M.; Stiff, P.; Friedberg, J. W
- Abstract
B Introduction: b CD19 CAR T-cell therapy (CD19 CTCT) is now the standard of care for many patients (pts) with relapsed/refractory large cell lymphoma (LCL), but nearly two-thirds of patients will still progress. Relapsed disease post CD19 CTCT is poorly responsive to subsequent therapies, and patient survival is dismal. SWOG 2114: A RANDOMIZED PHASE II TRIAL OF CONSOLIDATION THERAPY FOLLOWING CD19 CAR T-CELL TREATMENT FOR RELAPSED/REFRACTORY LARGE B-CELL OR GRADE IIIB FOLLICULAR LYMPHOMA.
- Subjects
CD19 antigen; FOLLICULAR lymphoma; T cells; STEM cell transplantation
- Publication
Hematological Oncology, 2023, Vol 41, p839
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3166_OT19